Floatz logo

Benadryl

Type 1 Papillary Renal Cell Carcinoma

Fred Hutchinson Cancer CenterN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Type 1 Papillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Tivantinib
National Cancer Institute (NCI)
Phase 2B
Crizotinib
National Cancer Institute (NCI)
Phase 2B
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2B
Carboplatin
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B

View all 15 →

Same molecule, other indications

Benadryl is also rated in:

Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →